Enasidenib Nitroso Impurity 2
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Enasidenib is used to treat acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation in patients who have not responded to other treatments or to those whose cancer has come back after treatment.Enasidenib Nitroso Impurity 2 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Enasidenib Nitroso Impurity 2 CAS NO: NA chemically represented as N-(4-((2-Hydroxy-2-methylpropyl)(nitroso)amino)-6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)nitrous amide. Synchemia is the leading manufacturing and exporter of Enasidenib Nitroso Impurity 2 . We supply Enasidenib Nitroso Impurity 2 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143812 |
| CAS No | NA |
| Mol.F. | C14H13D3N4O2 |
| Mol.Wt. | 275.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143813 |
| CAS No | NA |
| Mol.F. | C14H13D3N4O2 |
| Mol.Wt. | 275.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143814 |
| CAS No | NA |
| Mol.F. | C11H18N2O3 |
| Mol.Wt. | 226.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143815 |
| CAS No | NA |
| Mol.F. | C18H21F6N3O4 |
| Mol.Wt. | 457.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143816 |
| CAS No | NA |
| Mol.F. | C19H21FN4O5 |
| Mol.Wt. | 404.4 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143817 |
| CAS No | NA |
| Mol.F. | C11H6F2N2O5 |
| Mol.Wt. | 284.2 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143817 |
| CAS No | NA |
| Mol.F. | C11H6F2N2O5 |
| Mol.Wt. | 284.2 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143818 |
| CAS No | NA |
| Mol.F. | C10H4F2N2O5 |
| Mol.Wt. | 270.1 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143819 |
| CAS No | NA |
| Mol.F. | C13H10F2N2O5 |
| Mol.Wt. | 312.2 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143820 |
| CAS No | NA |
| Mol.F. | C19H38N6O8 |
| Mol.Wt. | 478.5g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143821 |
| CAS No | NA |
| Mol.F. | C20H40N6O8 |
| Mol.Wt. | 492.6 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143822 |
| CAS No | NA |
| Mol.F. | C20H40N6O8 |
| Mol.Wt. | 492.6 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143823 |
| CAS No | NA |
| Mol.F. | C20H40N6O8 |
| Mol.Wt. | 492.6 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143824 |
| CAS No | NA |
| Mol.F. | C20H40N6O8 |
| Mol.Wt. | 492.6 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143825 |
| CAS No | NA |
| Mol.F. | C20H40N6O10 |
| Mol.Wt. | 524.6 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143826 |
| CAS No | NA |
| Mol.F. | C20H40N6O10 |
| Mol.Wt. | 524.6 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |